North America Neoantigens Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. North America Neoantigens Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. North America Neoantigens Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. North America Neoantigens Market Regional Analysis

6.2 North America Neoantigens Market Revenue 2021-2028 (US$ Thousand)

6.3 North America Neoantigens Market Forecast Analysis

7. North America Neoantigens Market Analysis – by Treatment

7.1 Combination Therapy and Mono Therapy

7.1.1 Overview
7.1.2 Combination Therapy and Mono Therapy: North America Neoantigens Market – Revenue and Forecast, 2021-2028 (US$ Thousand)

8. North America Neoantigens Market Analysis – by Therapeutic Specialty

8.1 Gastrointestinal Cancer

8.1.1 Overview
8.1.2 Gastrointestinal Cancer: North America Neoantigens Market – Revenue and Forecast, 2021-2028 (US$ Thousand)

8.2 Lung Cancer

8.2.1 Overview
8.2.2 Lung Cancer: North America Neoantigens Market – Revenue and Forecast, 2021-2028 (US$ Thousand)

8.3 Solid Tumor

8.3.1 Overview
8.3.2 Solid Tumor: North America Neoantigens Market – Revenue and Forecast, 2021-2028 (US$ Thousand)

8.4 Urinary Systems Cancers

8.4.1 Overview
8.4.2 Urinary Systems Cancers: North America Neoantigens Market – Revenue and Forecast, 2021-2028 (US$ Thousand)

8.5 Melanoma

8.5.1 Overview
8.5.2 Melanoma: North America Neoantigens Market – Revenue and Forecast, 2021-2028 (US$ Thousand)

8.6 Head and Neck Cancer

8.6.1 Overview
8.6.2 Head and Neck Cancer: North America Neoantigens Market – Revenue and Forecast, 2021-2028 (US$ Thousand)

9. North America Neoantigens Market – North America Analysis

9.1 Overview

9.2 North America

9.2.1 North America Neoantigens Market Breakdown, by Key Country, 2024 and 2028 (%)
9.2.1.1 North America Neoantigens Market – Revenue and Forecast Analysis – by Country
9.2.1.1 US: North America Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.2.1.1.1 US: North America Neoantigens Market Breakdown, by Treatment
9.2.1.1.2 US: North America Neoantigens Market Breakdown, by Therapeutic Specialty

9.2.1.2 Canada: North America Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.2.1.2.1 Canada: North America Neoantigens Market Breakdown, by Treatment
9.2.1.2.2 Canada: North America Neoantigens Market Breakdown, by Therapeutic Specialty

9.2.1.3 Mexico : North America Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.2.1.3.1 Mexico : North America Neoantigens Market Breakdown, by Treatment
9.2.1.3.2 Mexico : North America Neoantigens Market Breakdown, by Therapeutic Specialty

10. Competitive Landscape

10.1 Heat Map Analysis

10.2 Company Positioning and Concentration

11. Industry Landscape

11.1 Overview

11.2 Market Initiative

11.3 Partnerships and Collaborations

11.4 Other Developments

12. Company Profiles

12.1 Advaxis, Inc.

12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments

12.2 Gradalis, Inc.

12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments

12.3 Gritstone Oncology

12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments

12.4 Medigene AG

12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments

12.5 Moderna, Inc.

12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments

12.6 Ziopharm Oncology, Inc

12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments

13. Appendix

13.1 About Business Market Insights

13.2 List of Abbreviations

North America Neoantigens Market

Analysis By Treatment (Combination Therapy and Mono Therapy) and Therapeutic Specialty (Gastrointestinal Cancer, Lung Cancer, Solid Tumor, Urinary Systems Cancers, Melanoma, Head and Neck Cancer, and Others)